glp-1 gi obstruction law firm in west virginia Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? GLP-1 | Summary
Description
Cluster 3 included GI symptoms such as nausea, pancreatitis, rash, and vomiting
Zanoveli JM, Morais HD, Dias IC, Schreiber AK, Souza CP, Cunha JM
Recent landmark trials, particularly the SELECT study, have provided compelling evidence for cardiovascular benefits in non-diabetic obese patients, potentially reshaping our understanding of obesity treatment paradigms
If GI AEs are present, then the authors recommend a more cautious approach, with slower uptitration (every 48 weeks)
It's part of the story
